-
Posted by
Two Blokes May 28 -
Filed in
Stock
-
2 views
Harrow has successfully leveraged its compounding pharmacy roots to drive rapid branded drug growth. Revenue has grown at a steady 40% CAGR for a decade & EBITDA has grown even more sharply. Management is guiding for this to not only continue, but actually accelerate. Harrow's operating leverage is plainly evident in the data. EBITDA margins have risen sharply as the company has grown, and management has guided for this to accelerate in 2025.
